Back

Long-term efficacy of mavacamten on cardiac structure and function in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: long-term extension of EXPLORER-CN trial

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Zhuang Tian

Peking Union Medical College Hospital, Beijing (China)

6 More presentations in this session

Presentation thumbnail
Characterisation of interrelations among myocardial work parameters in patients with hypertrophic cardiomyopathy: differences between non-obstructive and obstructive disease
Doctor A. Kormanyos (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
The role of stress echocardiography to unmask latent LVOT obstruction in hypertrophic cardiomyopathy
Doctor D. Faro (Catania, IT)
Abstract Slides Video
Presentation thumbnail
The influence of genotype on the phenotype and prognosis of patients with hypertrophic cardiomyopathy
Miss I. Conde (Braga, PT)
Abstract Slides Video
Presentation thumbnail
Examining ECG's performance as a screening method for hypertrophic cardiomyopathy: phenotypic correlations and evaluation
Doctor I. Martins Moreira (Vila Real, PT)
Abstract Slides Video
Presentation thumbnail
Decrease of ECG hypertrophy indices during mavacamten treatment in obstructive hypertrophic cardiomyopathy
Doctor R. Sepp (Szeged, HU)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertrophic cardiomyopathy

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Long-term efficacy and safety of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: long-term extension of EXPLORER-CN trial
thumbnail
Congress Presentation
Long-term efficacy of mavacamten on health status in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: results from long-term extension of the EXPLORER-CN trial
thumbnail
Congress Presentation
Mavacamten treatment in obstructive hypertrophic cardiomyopathy for up to 30 weeks: An integrated analysis of cardiac magnetic resonance data from a diverse population in randomized clinical trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources